{"id":"eculizumab-ivmp","safety":{"commonSideEffects":[{"rate":null,"effect":"Meningococcal infection"},{"rate":null,"effect":"Infusion reactions"},{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Immunosuppression-related infections"},{"rate":null,"effect":"Hypertension"}]},"_chembl":{"chemblId":"CHEMBL1201828","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Eculizumab is a C5 complement inhibitor that blocks the terminal complement cascade, preventing formation of the membrane attack complex and reducing complement-mediated hemolysis and inflammation. IVMP is a high-dose corticosteroid that suppresses immune cell activation and proliferation. Together, this combination targets both complement-driven and steroid-responsive immune pathways.","oneSentence":"Eculizumab inhibits the complement C5 protein to prevent inflammatory cell destruction, while IVMP (intravenous methylprednisolone) provides corticosteroid immunosuppression.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:36:03.411Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Paroxysmal nocturnal hemoglobinuria (PNH)"},{"name":"Atypical hemolytic uremic syndrome (aHUS)"},{"name":"Severe autoimmune hemolytic anemia"}]},"trialDetails":[{"nctId":"NCT07410039","phase":"PHASE4","title":"Therapy in the Acute Phase of NMOSD: A Multicenter Prospective Real-World Study","status":"RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2026-02-01","conditions":"Neuromyelitis Optica Spectrum Disorder Attack","enrollment":200},{"nctId":"NCT07420296","phase":"PHASE4","title":"Modified Zipper Therapy for AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder","status":"RECRUITING","sponsor":"Tianjin Medical University General Hospital","startDate":"2026-01-01","conditions":"Neuromyelitis Optica Spectrum Disorders (NMOSD)","enrollment":198},{"nctId":"NCT07184840","phase":"PHASE2","title":"Eculizumab For the Acute Attack of Neuromyelitis Optica Spectrum Disorder","status":"RECRUITING","sponsor":"Tianjin Medical University General Hospital","startDate":"2025-09-09","conditions":"Neuromyelitis Optica Spectrum Disorder Attack","enrollment":110},{"nctId":"NCT07182409","phase":"","title":"Efficacy and Safety of Monoclonal Antibody in Acute Phase of Neuromyelitis Optica Spectrum Disorder","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Chongqing Medical University","startDate":"2025-10-01","conditions":"NMOSD","enrollment":40},{"nctId":"NCT06673394","phase":"PHASE2","title":"Eculizumab For Acute Attack of Neuromyelitis Optica Spectrum Disorder","status":"WITHDRAWN","sponsor":"Tianjin Medical University General Hospital","startDate":"2025-09-03","conditions":"Neuromyelitis Optica Spectrum Disorder Attack","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Eculizumab+IVMP","genericName":"Eculizumab+IVMP","companyName":"Chinese PLA General Hospital","companyId":"chinese-pla-general-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Eculizumab inhibits the complement C5 protein to prevent inflammatory cell destruction, while IVMP (intravenous methylprednisolone) provides corticosteroid immunosuppression. Used for Paroxysmal nocturnal hemoglobinuria (PNH), Atypical hemolytic uremic syndrome (aHUS), Severe autoimmune hemolytic anemia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}